等待开盘 03-28 09:30:00 美东时间
+0.100
+9.71%
Entrada Therapeutics secures EU authorization for ELEVATE-45-201, a Phase 1/2 study of ENTR-601-45 for Duchenne muscular dystrophy patients amenable to exon 45 skipping. The study aims to assess safety, tolerability, and efficacy, with initiation planned for Q3 2025. ENTR-601-45 is an exon-skipping therapy designed to restore dystrophin production, addressing a significant unmet need in this DMD subpopulation.
2025-05-28 11:00